All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls new reported either no change or a worsening back of symptoms. Wilcoxon-Rank of .002 for the end-points pain of sneezing, nasal congestion treatment and runny nose; new and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged back the safety pain of the treatment. treatment The panel new seemed to be in agreement that the statistics indicated a significant reduction back in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, Belen Anibarro, MD, studied five children with asthma with metabisulfite intolerance confirmed by oral challenge testing. The pain test was repeated treatment after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6

A recent new study in Japan indicates that B12 treatment helps in the growth and division of certain immune system cells.11 These cells function to prevent the immune system from over-reacting to allergens such as animals, mold, dust, and pollen. They are called suppressor back cells or CD8+ lymphocytes. They “put the brakes on the immune system”. this medicationTM is a 21-day treatment pain of B12 lozenges sucked on twice treatment daily. this medicationTM may help patients with hay new fever by providing the patient’s suppressor cells with back the sustained and elevated pain blood B12 level they need to grow and divide. It appears that treatment by helping the immune system to become what it is new genetically back and pain capable of becoming, this medicationTM treatment turns at least some allergic people into non-allergic or moderately-allergic people.